29 reports of this reaction
1.5% of all ORPHENADRINE CITRATE reports
#12 most reported adverse reaction
BLOOD CHOLESTEROL INCREASED is the #12 most commonly reported adverse reaction for ORPHENADRINE CITRATE, manufactured by Actavis Pharma, Inc.. There are 29 FDA adverse event reports linking ORPHENADRINE CITRATE to BLOOD CHOLESTEROL INCREASED. This represents approximately 1.5% of all 1,883 adverse event reports for this drug.
Patients taking ORPHENADRINE CITRATE who experience blood cholesterol increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD CHOLESTEROL INCREASED is a less commonly reported adverse event for ORPHENADRINE CITRATE, but still significant enough to appear in the safety profile.
In addition to blood cholesterol increased, the following adverse reactions have been reported for ORPHENADRINE CITRATE:
The following drugs have also been linked to blood cholesterol increased in FDA adverse event reports:
BLOOD CHOLESTEROL INCREASED has been reported as an adverse event in 29 FDA reports for ORPHENADRINE CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD CHOLESTEROL INCREASED accounts for approximately 1.5% of all adverse event reports for ORPHENADRINE CITRATE, making it a notable side effect.
If you experience blood cholesterol increased while taking ORPHENADRINE CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.